In a recent update from the Patent Trial and Appeal Board, a petition filed by the biotechnology company Microbiotica has been rejected. The company earlier had sought a post-grant review of a cancer treatment patent that is currently held by the University of Texas System.
The University of Texas System could be taking a sigh of relief following the Board’s decision, providing them with the unique right of the patent’s usage, exploring its full potential without any legal interference.
While Microbiotica’s intent behind the petition remains undisclosed, this rejection might defer any plans they had related to the cancer treatment patent. It may prompt them to consider other legal avenues or examine different technological approaches to their work.
For more details, refer to the original report on Law360.